The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.
By E. Nkhoma, Charles Poole, V. Vannappagari, S. Hall, E. Beutler. Blood Cells, Molecules & Diseases, 2009
682 citations recorded by the source corpus.
Glucose-6-phosphate deficiency is the most prevalent enzyme deficiency, with an estimated 400 million people affected worldwide. This inherited deficiency causes neonatal hyperbilirubinemia and chronic hemolytic anemia. Although most affected individuals are asymptomatic, exposure to oxidative stressors such as certain drugs or infection, can elicit acute hemolysis. To characterize the global prevalence of G6PD deficiency, we conducted a systematic review of the G6PD deficiency literature, drawing studies from various databases, including MEDLINE/Pubmed and Biosis. Selected studies included cross-sectional and longitudinal studies published between 1960 and 2008. Additionally, meta-analytic procedures were employed to assess the degree of heterogeneity amongst prevalence estimates and, where appropriate, pool them. The searches yielded a total of 280 prevalence estimates, corresponding to 88 countries. The highest prevalence rates were reported among Sub-Saharan African countries, even after adjusting for assessment method. Meta-analysis revealed a high degree of heterogeneity for regional and global prevalence estimates. This heterogeneity in reported estimates appeared to be due to differences in G6PD deficiency assessment and diagnostic procedures. The magnitude and variation in global, regional, and country-level prevalence rates of G6PD deficiency are of public health import, particularly in planning programs to improve neonatal health and in the distribution of various medications, especially antimalarial drugs, as G6PD deficiency is most prevalent in malaria-endemic areas.
Subfields: Genetics, Pediatrics, Perinatology and Child Health, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/43114b7e33d204e9f277c3ef67185900e2d09587
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. Osterhaus
- P. Koraka
- B. Martina
Citations in the corpus
- Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. (2022, neutral): “The TcB or TSB should be measured between 24”
- Dengue Virus Pathogenesis: an Integrated View (2009, background): “Deficiency in G6PD, a ubiquitous X-linked enzyme, is the most common enzyme deficiency worldwide, with high prevalence seen in the African population (175).”
- Coupling between protein stability and catalytic activity determines pathogenicity of G6PD variants (2017, neutral): “2592 Cell Reports 18, 2592–2599, March 14, 2017 a 2017 The Autho This is an open access article under the CC BY license (http://creative against malaria (Nkhoma et al., 2009; Vulliamy et al., 1992).”
- Glucose-6-Phosphate Dehydrogenase, NADPH, and Cell Survival (2012, background): “I am often asked, ‘‘how about all of those G6PD-deficient people in the world?’’ (3).”